Methods and compounds for prevention of graft rejection
CA 2130802 A1 · Owner: Beth Israel Hospital Association · Inventors: Rubin-Kelley, Vickie E.; Strom, Terry; Libermann, Towia
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a method of preventing graft rejection by inducing a state of local immunosuppression at the transplant site with expression of recombinant proteins by the allograft. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65 ·C for 15 minutes blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro), is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 1, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 1, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 1, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.